Speaking at the recent Transcatheter Cardiovascular Therapeutics (TCT) Conference, prominent cardiovascular device investigator Deepak Bhatt advised device investigators to listen to the FDA when designing trials, especially when it comes to issues such as use of sham treatments.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?